Status:
COMPLETED
Effects of High-dose Intravenous Selenium (Selenase®) in Adult Patients Subjected to Elective All-cause Heart Surgery
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Heart; Surgery, Heart, Functional Disturbance as Result
Self Efficacy
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Selenoenzymes play a major role in protecting cells against lipid peroxidation and they are involved in the inflammatory response regulation. The degree of selenium deficiency correlates with disease ...
Detailed Description
Selenium is a essential micronutrient that is present in form of selenocysteine in many enzymes. Selenoenzymes play a major role in protecting cells against lipid peroxidation and they are involved in...
Eligibility Criteria
Inclusion
- written informed consent
- males and females age ≥ 18 years
- patients undergoing an elective heart surgery
- normal renal function (serum creatinine ≤ 200 μmol/l)
Exclusion
- pregnancy
- lack of written concent
- emergency operation
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
410 Patients enrolled
Trial Details
Trial ID
NCT01141556
Start Date
December 1 2010
End Date
September 1 2012
Last Update
October 25 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital Luzern
Lucerne, Canton of Lucerne, Switzerland, 6016
2
Departement of Anaesthesia and Intensive Care, University Hospital of Basel
Basel, Switzerland
3
Kantonsspital Luzern
Lucerne, Switzerland, 6016